There is currently no proven treatment available against the sickle disease, however, scientists now claim First Patient In ...

Connecticut is now participating in a new federal program aimed at expanding treatment access for patients with sickle cell ...

For many people, drinking water is something done without much thought. But for those living with sickle cell disease, water is more than a daily habit. It is a critical component of health management ...

Challenges persist despite promising advance In January 2025, the National Institute for Health and Care Excellence (NICE) approved the use of the gene editing therapy exagamglogene autotemcel ...

What are the main benefits of treatment with exa-cel and what are the risks? Exa-cel provides a potential cure for sickle cell disease in a one-time treatment. The phase 3 clinical trial that led to ...

Patients who received lovo-cel had durable remissions and reductions in vaso-occlusive events, pain crises, and hospitalizations in the longest running gene therapy trial for sickle cell disease.

With Casgevy, 93.5% of patients were free from severe vaso-occlusive crisis episodes for at least 12 consecutive months during the two-year follow-up period.

SAN DIEGO — Etavopivat reduced the annualized vaso-occlusive crises rate vs. placebo for people with sickle cell disease, according to study data presented at ASH Annual Meeting and Exposition ...

IV lactated Ringer solution should be the preferred volume-expanding fluid for resuscitation of patients with sickle cell disease who experience vaso-occlusive episodes at the time of hospital ...

Lactated Ringer vs Normal Saline Solution During Sickle Cell Vaso-Occlusive Episodes. JAMA Internal Medicine, 2024; DOI: 10.1001/jamainternmed.2024.4428 ...

The treatment is approved for people 12 and older with severe sickle cell disease who get recurrent pain syndromes known as vaso-occlusive crises, in which blood flow is blocked due to sickle cells.

More information: Augusta K. Alwang et al, Lactated Ringer vs Normal Saline Solution During Sickle Cell Vaso-Occlusive Episodes, JAMA Internal Medicine (2024). DOI: 10.1001/jamainternmed.2024.4428 ...